The estimated Net Worth of David Shook is at least $787 Tausend dollars as of 18 June 2024. David Shook owns over 456 units of Nkarta stock worth over $748,084 and over the last 2 years David sold NKTX stock worth over $39,124.
David has made over 5 trades of the Nkarta stock since 2023, according to the Form 4 filled with the SEC. Most recently David sold 456 units of NKTX stock worth $2,554 on 18 June 2024.
The largest trade David's ever made was selling 3,552 units of Nkarta stock on 16 January 2024 worth over $31,044. On average, David trades about 661 units every 58 days since 2023. As of 18 June 2024 David still owns at least 116,524 units of Nkarta stock.
You can see the complete history of David Shook stock trades at the bottom of the page.
David's mailing address filed with the SEC is C/O NKARTA, INC., 1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Nkarta have traded over $2,620,353 worth of Nkarta stock and bought 14,255,554 units worth $205,999,973 . The most active insiders traders include Plc Gsk, Ali Behbahani und Holdings A/S Novo. On average, Nkarta executives and independent directors trade stock every 24 days with the average trade being worth of $1,501,195. The most recent stock trade was executed by Alicia J. Hager on 16 July 2024, trading 3,396 units of NKTX stock currently worth $27,168.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Nkarta executives and other stock owners filed with the SEC include: